Clinical aspects of psoriatic arthritis: one year in review 2024

Psoriatic arthritis is a very pleomorphic inflammatory disease characterised by its association with psoriasis and the development of a wide spectrum of comorbidities that can impact patients’ prognosis and quality of life. In recent years, several new drugs have been developed, showing significant efficacy in alleviating symptoms and signs, while maintaining a generally favourable safety profile. Despite these advancements, the management of PsA remains potentially suboptimal. Indeed, a percentage of patients do not respond to therapies, or they may improve only in limited outcomes, resulting in a challenge for the management of the burden of disease. In this paper we reviewed the literature on PsA from January 1st 2022 to July 1st 2024.